Laura Shawver - 03 Jul 2023 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Role
Director
Signature
/s/ Kathleen Scott, Attorney-in-Fact
Issuer symbol
SPRY
Transactions as of
03 Jul 2023
Net transactions value
-$474,703
Form type
4
Filing time
06 Jul 2023, 20:55:41 UTC
Previous filing
28 Jun 2023
Next filing
07 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRY Common Stock Options Exercise $33,680 +26,520 +13% $1.27* 236,866 03 Jul 2023 Direct
transaction SPRY Common Stock Sale $178,347 -26,520 -11% $6.72 210,346 03 Jul 2023 Direct F1, F2
transaction SPRY Common Stock Options Exercise $39,512 +31,112 +15% $1.27* 241,458 05 Jul 2023 Direct
transaction SPRY Common Stock Sale $199,552 -31,112 -13% $6.41 210,346 05 Jul 2023 Direct F1, F3
transaction SPRY Common Stock Options Exercise $42,558 +33,510 +16% $1.27* 243,856 06 Jul 2023 Direct
transaction SPRY Common Stock Sale $212,554 -33,510 -14% $6.34 210,346 06 Jul 2023 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -26,520 -13% $0.000000 176,477 03 Jul 2023 Common Stock 26,520 $1.27 Direct F5
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -31,112 -18% $0.000000 145,365 05 Jul 2023 Common Stock 31,112 $1.27 Direct F5
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -33,510 -23% $0.000000 111,855 06 Jul 2023 Common Stock 33,510 $1.27 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $6.62 to $6.81, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $6.21 to $6.75, inclusive. The Reporting Person undertakes to provide the the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $6.10 to $6.45, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein.
F5 Immediately exercisable.